Characterization of angiotensin II antagonism displayed by Ib, a novel nonpeptide angiotensin AT(1) receptor antagonist

Eur J Pharmacol. 2008 Jul 28;589(1-3):220-4. doi: 10.1016/j.ejphar.2008.05.007. Epub 2008 May 20.

Abstract

The pharmacologic profile of Ib, 5-n-butyl-4-{4-[2-(1H-tetrazole-5-yl)-1H-pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6-dichloridephenyl)-3H-1,2,4-triazol-3-one, a novel nonpeptide angiotensin AT(1) receptor antagonist, was investigated by receptor-binding studies, functional in vitro assays with rabbit and rat aorta, and in vivo experiments in rats. Ib inhibited [(125)I] angiotensin II binding to AT(1) receptors in rat liver membranes (K(i)=2.5+/-0.5 nM) and did not interact with AT(2) receptors in bovine cerebellar membranes. In functional studies with rat and rabbit aorta, Ib inhibited the contractile response to angiotensin II (pD(2)' value: 7.43 and 7.29, respectively) with a significant reduction in the maximum. In pithed rats, Ib inhibited the angiotensin II induced pressor response in a dose-related manner. After intravenous administration, Ib produced a dose-dependent antihypertensive effects in spontaneously hypertensive rats and renal hypertensive rats. These results suggest that Ib is a potent angiotensin AT(1) selective receptor antagonist with a mode of insurmountable antagonism.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin II / metabolism*
  • Angiotensin II Type 1 Receptor Blockers / administration & dosage
  • Angiotensin II Type 1 Receptor Blockers / metabolism
  • Angiotensin II Type 1 Receptor Blockers / pharmacology*
  • Animals
  • Antihypertensive Agents / administration & dosage
  • Antihypertensive Agents / metabolism
  • Antihypertensive Agents / pharmacology*
  • Aorta, Thoracic / drug effects
  • Aorta, Thoracic / metabolism
  • Blood Pressure / drug effects
  • Cattle
  • Cerebellum / drug effects
  • Cerebellum / metabolism
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Hypertension / drug therapy*
  • Hypertension / metabolism
  • Hypertension / physiopathology
  • Injections, Intravenous
  • Liver / drug effects
  • Liver / metabolism
  • Losartan / pharmacology
  • Male
  • Protein Binding
  • Pyrroles / administration & dosage
  • Pyrroles / metabolism
  • Pyrroles / pharmacology*
  • Rabbits
  • Rats
  • Rats, Inbred SHR
  • Rats, Sprague-Dawley
  • Receptor, Angiotensin, Type 1 / drug effects*
  • Receptor, Angiotensin, Type 1 / metabolism
  • Time Factors
  • Triazoles / administration & dosage
  • Triazoles / metabolism
  • Triazoles / pharmacology*
  • Vasoconstriction / drug effects

Substances

  • 5-n-butyl-4-(4-(2-(1H-tetrazole-5-yl)-1H-pyrrol-1-yl)phenylmethyl)-2,4-dihydro-2-(2,6-dichloridephenyl)-3H-1,2,4-triazol-3-one
  • Angiotensin II Type 1 Receptor Blockers
  • Antihypertensive Agents
  • Pyrroles
  • Receptor, Angiotensin, Type 1
  • Triazoles
  • Angiotensin II
  • Losartan